Osteochondrodysplasias: Clinical Trials

36 trials for Osteochondrodysplasias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 6 active not recruiting, 5 terminated, 4 recruiting. 36 Phase 3, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 336Completed 14, Active not recruiting 6, Terminated 5, Recruiting 4, Unknown 4, Enrolling by invitation 2, Not yet recruiting 1
Phase 212Completed 4, Recruiting 3, Enrolling by invitation 2, Active not recruiting 1, Terminated 1, Unknown 1

Follow Osteochondrodysplasias: new trials by email Literature Review of Osteochondrodysplasias trials Research Report on Osteochondrodysplasias

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia
Dual therapy with navepegritide and lonapegsomatropin, Dual therapy with navepegritide and placebo for lonapegsomatropin, Dual therapy with lonapegsomatropin and placebo for navepegritide - Achondroplasia
Phase 3Not yet recruitingAscendis Pharma A/S1442026-11-012026-11-12
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
BMN 333, Vosoritide Injection [Voxzogo] - Achondroplasia
Phase 2 / Phase 3RecruitingBioMarin Pharmaceutical1602026-04-202026-10-22
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
Vitamin D, Calcium - Osteogenesis Imperfecta
Phase 3RecruitingAmgen712026-03-182026-11-17
An Interventional Study of Infigratinib in Children With Hypochondroplasia
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia
Phase 2 / Phase 3Enrolling by invitationQED Therapeutics, a BridgeBio company242025-04-222026-07-16
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 / Phase 3RecruitingBicara Therapeutics6502025-01-282026-10-29
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study)
KK8398 - Achondroplasia
Phase 3Active not recruitingKyowa Kirin Co., Ltd.132024-12-012026-10-08
Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
setrusumab - Osteogenesis Imperfecta
Phase 3Active not recruitingUltragenyx Pharmaceutical Inc62024-10-252026-09-28
Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome
Etanercept, Placebo - SAPHO Syndrome
Phase 2 / Phase 3RecruitingNational Institute of Geriatrics, Rheumatology and Rehabilitation, Poland602024-09-042026-04-13
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
Vosoritide, Placebo - Hypochondroplasia
Phase 3CompletedBioMarin Pharmaceutical812024-06-172026-11-12
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Romosozumab, Bisphosphonate - Osteogenesis Imperfecta
Phase 3Active not recruitingAmgen1112024-04-222026-05-27
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day - Achondroplasia
Phase 3CompletedQED Therapeutics, a BridgeBio company1142023-11-102026-03-17
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
TransCon CNP - Achondroplasia
Phase 2 / Phase 3Enrolling by invitationAscendis Pharma Growth Disorders A/S1402023-06-212026-08-17
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
Bisphosphonate, Setrusumab - Osteogenesis Imperfecta
Phase 3Active not recruitingUltragenyx Pharmaceutical Inc692023-06-142026-10-20
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
Navepegritide (TransCon CNP), Placebo for Navepegritide (TransCon CNP) - Achondroplasia
Phase 2 / Phase 3CompletedAscendis Pharma Growth Disorders A/S842023-03-032026-07-14
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
Pioglitazone 30mg, Empagliflozin 10 MG - Non Alcoholic Steatohepatitis
Phase 3UnknownTanta University562022-11-012022-11-04
Setrusumab vs Placebo for Osteogenesis Imperfecta
Setrusumab, Placebo - Osteogenesis Imperfecta
Phase 2 / Phase 3Active not recruitingUltragenyx Pharmaceutical Inc1832022-02-212026-10-20
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
M7824, Placebo, Gemcitabine - Biliary Tract Cancer, Cholangiocarcinoma
Phase 2 / Phase 3TerminatedEMD Serono Research & Development Institute, Inc.3092019-09-202023-11-14
Effects of Soy Isoflavone on Bone Health Among Saudi Female Students Imam Abdulrahman Bin Faisal University.
Soy Isoflavone supplement - Soy Isoflavone Effect, Bone Density, Low
Phase 3CompletedImam Abdulrahman Bin Faisal University282018-12-122023-09-28
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
Denosumab, Alternative osteoporosis medications - Osteogenesis Imperfecta (OI)
Phase 3TerminatedAmgen752018-07-262022-12-20
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
BMN 111 - Achondroplasia
Phase 3Active not recruitingBioMarin Pharmaceutical1192017-12-122026-03-13

Showing 20 of 36. Sign in to see all of them.

Narrower conditions

Osteogenesis Imperfecta (11)  ·  Achondroplasia (8)  ·  Genetic Diseases, Inborn (7)  ·  Bone Diseases (6)  ·  Dwarfism (6)  ·  Musculoskeletal Diseases (6)  ·  Camurati-Engelmann Syndrome (5)  ·  Osteopetrosis (4)  ·  Bone Diseases, Developmental (3)  ·  Collagen Diseases (2)  ·  Hip Dislocation, Congenital (2)  ·  Hypochondroplasia (2)  ·  Mucopolysaccharidosis IV (2)  ·  Osteoarthritis (2)

Broader conditions

Bone Diseases, Developmental (33)  ·  Bone Diseases (30)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (30)  ·  Musculoskeletal Diseases (30)  ·  Genetic Diseases, Inborn (21)  ·  Skin and Connective Tissue Diseases (17)  ·  Connective Tissue Diseases (16)  ·  Collagen Diseases (11)  ·  Endocrine System Diseases (7)  ·  Dwarfism (4)  ·  Metabolic Diseases (4)  ·  Neoplasms (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Osteosclerosis (4)

Interventions

vosoritide (4)  ·  Busulfan (3)  ·  Cyclophosphamide (3)  ·  setrusumab (3)  ·  Alemtuzumab (2)  ·  Denosumab (2)  ·  Diphosphonates (2)  ·  Risedronic Acid (2)  ·  fludarabine (2)  ·  fludarabine phosphate (2)  ·  infigratinib (2)  ·  thymoglobulin (2)  ·  Anastrozole (1)  ·  Antilymphocyte Serum (1)  ·  Calcitriol (1)

Sponsors

Amgen (4)  ·  BioMarin Pharmaceutical (4)  ·  Ultragenyx Pharmaceutical Inc (3)  ·  Ascendis Pharma Growth Disorders A/S (2)  ·  DePuy International (2)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2)  ·  QED Therapeutics, a BridgeBio company (2)  ·  Ascendis Pharma A/S (1)  ·  Bicara Therapeutics (1)  ·  Columbia University (1)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  FDA Office of Orphan Products Development (1)  ·  Fondazione IRCCS Policlinico San Matteo di Pavia (1)  ·  Fudan University (1)  ·  Imam Abdulrahman Bin Faisal University (1)

Countries

United States (22)  ·  Australia (15)  ·  United Kingdom (15)  ·  Germany (14)  ·  Canada (13)  ·  Italy (13)  ·  Spain (13)  ·  France (12)  ·  Japan (10)  ·  Poland (10)  ·  Belgium (7)  ·  Hungary (5)  ·  Turkey (Türkiye) (5)  ·  Austria (4)  ·  China (4)

Top investigators

Joan C Marini, M.D. (2)  ·  Amir Ali Hamidieh, MD (1)  ·  Dietrich H Wenderoth, MD (1)  ·  Eloisa Arbustini, MD,FESC,FACC (1)  ·  Francis H. Glorieux, MD, PhD (1)  ·  James Garvin, MD, PhD (1)  ·  Jiayi Chen, MD (1)  ·  L. Lyndon Key, Jr. (1)  ·  Luigi Tavazzi, MD,FESC,FACC (1)

Results publications

PMID 42470570, PMID 38649657, PMID 39305160, PMID 39740666, PMID 16601194, PMID 17188619, PMID 17911499, PMID 19430350, PMID 23927913, PMID 24474088, PMID 32461347, PMID 34431071, PMID 38875119, PMID 41247754, PMID 42144862, PMID 42370681, PMID 42713641

NIH funding

2023 (3), 2014 (1), 2015 (1), 2017 (1), 2018 (1), 2019 (1)